MedTrace Logo

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis

NCT02474069 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 772

Last updated 2019-07-05

Study results available
· View outcomes & findings →

Summary

This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis. The purpose of the study is to explore the effects of dosage interval shorteng to achieve PASI 90 at week 32 for patients who had less than almost clear skin at week 16.

Conditions

  • Moderate to Severe Plaque-type Psoriasis

Interventions

DRUG

Secukinumab

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-08
Primary Completion
2016-09-15
Completion
2016-09-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02474069 on ClinicalTrials.gov